Gregory Oakes Named as President and Chief Executive Officer of Landos Biopharma

Chartwell Partners is pleased to have worked with public, clinical stage, autoimmune disease
focused biopharmaceutical company, Landos Biopharma, to recruit Greg Oakes as President and Chief
Executive Officer. Mr. Oakes brings a wealth of experience building and leading organizations through
the development and commercialization of life changing medicines. He most recently served as
President, North America, Executive Vice President and member of the Executive Committee of Vifor
Pharma. Prior to that position, he served as Corporate Vice President and Global Integration Lead for
Otezla® at Amgen from 2019 to 2020, overseeing the integration of the $2 billion brand acquired from
Celgene, and positioning it for sustained growth. Mr. Oakes was Corporate Vice President and General
Manager, US for Celgene’s Inflammation and Immunology franchise. He held earlier leadership roles at
Amgen, Novartis International AG and Schering-Plough (Merck). Mr. Oakes brings more than 25 years of
pharmaceutical industry experience leading development stage programs through to successful
commercialization.